Dr Reddy's | Zee News

Advertisement

Dr Reddy's News

01 Jul 2021

Dr Reddy’s denied permission to conduct phase 3 trials of Sputnik Light

Dr Reddy's has been denied permission to conduct phase 3 trials for Sputnik Light vaccine in India. Sputnik Light is a single-dose vaccine that was found to be 79.4 per cent effective against the coronavirus during trials on Russians. Earlier on Tuesday (June 29, 2021), Dr Reddy's, a Hyderabad based pharmaceutical company, had said that the commercial launch of Sputnik V is likely to be postponed.

29 Jun 2021

COVID: Commercial launch of Sputnik V vaccine may be deferred, says Dr Reddy's

The wait for commercial launch of Sputnik V COVID-19 vaccine is going to continue. Dr Reddy's Laboratories on June 29 said that it may be deferred. Hyderabad based pharmaceutical company said launch may be postponed due to dependency on imported consignments.

28 May 2021

Dr Reddy’s fixes price of DRDO’s 2-DG anti-COVID drug at Rs 990 per sachet

2-DG anti-COVID-19 drug price has been fixed at Rs 990 per sachet. Union Defence Minister Rajnath Singh said that 10,000 sachets of 2-DG will be available in the market from Thursday (May 27). earlier, Dr Reddy's had stated that the anti-COVID-19 drug is expected to launch in the market by mid-June.

20 May 2021

DRDO’s anti-COVID drug 2-DG likely to be available by mid-June: Dr Reddy's

Commercial launch and supply of 2-DG to major government and private hospitals is expected to commence in mid-June, Dr Reddy's said. On May 17, Defence Minister Rajnath Singh had released the first batch of 2-DG. The drug was approved for emergency use as an adjunct therapy in moderate to severe COVID-19 patients on DCGI on May 1.

Sputnik V vaccine

14 May 2021

Russia’s Sputnik V COVID-19 vaccine to be available in India soon

Sputnik V vaccine to be available in 10 days. First batch/consignment of Sputnik V reached on 1 May. 3 lakh doses of the Russian vaccines will be available in the market soon.

23 Aug 2017

Sensex jumps for 2nd day, up 276 points; Infosys shapes up

Revival of buying interest in the recently battered Infosys, banking and financial stocks drove the market higher.

23 Feb 2017

634 drugs on NPPA's price ceiling non-compliant list

As many as 634 drugs of various strengths produced by firms, including Cipla, Abbott, Astrazeneca and Dr Reddy's, are "suspected" to be non-compliant with ceiling prices as notified by NPPA.

Dr Reddy's Laboratories

17 Feb 2016

Dr Reddy's board approves share buyback for Rs 1,569.4 crore

Drug major Dr Reddy's will buyback around 44.85 lakh shares, accounting for about 2.6 percent of the existing paid up capital of the company, for up to Rs 1,569.4 crore.

26 Nov 2015

Antim Baazi: Sun Pharma & Dr Reddys

Dr Reddy's Laboratories

26 Nov 2015

USFDA gives Dr Reddy's addl time to respond to warning letter

Dr Reddy's Laboratories Ltd (DRL) Thursday said the USFDA has extended the time-frame for replying to the warning letter issued to the company by about two weeks to December 7.

18 Nov 2015

Dr Reddy's buys IPR for anti-coagulant drug for $17.5 mn

The company had earlier inked a term sheet for this transaction in September.

Dr Reddy's Laboratories

29 Oct 2015

Dr Reddy's Lab Q2 net profit rises 26% to Rs 722 crore

Aided by good sales growth coupled with new product launches, drug major Dr Reddy's Laboratories Thursday reported a 25.74 percent jump in consolidated net profit at Rs 721.89 crore for the second quarter ended September 30.

Dr Reddy's Laboratories

06 Aug 2015

Dr Reddy's to market three Amgen drugs in India

Dr Reddy's Laboratories on Thursday said it has inked a pact with US-based biotechnology firm Amgen to market its three drugs used to treat heart diseases and cancer in India.

19 Jun 2015

Dr Reddy's launches hair growth supplement

The supplement provides key nutrients needed for maintaining healthy hair and according to the company, has a unique formula including grape seed extract containing potent antioxidants.

Dr Reddy's Laboratories

12 May 2015

Dr Reddy's Lab to enter Japanese market through a partner

Pharmaceutical major Dr Reddy's Laboratories Tuesday said it has plans to enter Japanese market through partnerships for specific products.

12 May 2015

Dr Reddy's Q4 net rises 8% to Rs 519 crore

The company had posted a net profit of Rs 481.60 crore for the corresponding period of previous fiscal, it said in a filing to the BSE.

23 Mar 2015

Dr Reddy's to launch Hepatitis C drug in India

Dr Reddy's Laboratories today entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

19 Dec 2014

Dr Reddy's acquires Habitrol brand

City-based drugmaker Dr Reddy's Laboratories has acquired Habitrol brand, a nicotine replacement therapy transdermal patch, from Novartis Consumer Health Inc.

26 Nov 2014

Dr Reddy's plant gets USFDA fiat on suspected lapses

The company is in the process of responding to the FDA's observations, a Dr Reddy's spokesperson said.

24 Nov 2014

Dr Reddy's launches Docetaxel injection in US

Dr Reddy's Laboratories has launched Docetaxel injection USP 20 mg/mL and 80 mg/4 mL, a generic version of Taxotere (docetaxel injection) in the US market.

Loading...

NEWS ON ONE CLICK